Cramer always has his eye out for the next big idea, especially privately-held companies making big waves in their industry. His attention recently turned to Blaze Pizza, backed by basketball superstar LeBron James.
In 2015, James decided not to renew his deal with McDonald's and instead endorsed Blaze Pizza. In an interview on "Mad Money," Blaze's Chief Operating Officer Jim Mizes chronicled the evolution of James's involvement with the company from investor to spokesperson and now a franchisee partnered with Larry Levy.
"He saw what Blaze Pizza and what this category could be, so he started as an investor, and then became a franchisee … And then he was so into Blaze that he came all in," Mizes said.
With this year an ugly one for biotech, situations like the one with Mylan's EpiPen have thrust drug pricing back into the public eye.
But that doesn't mean every biotech company is struggling. Spark Therapeutics has continued to be an outperformer. It was created in 2013 through the acquisition of intellectual property rights for various programs from the Children's Hospital of Philadelphia and other institutions.
Spark is a developmental stage biotech that is focused on gene therapy, with a stock that is up nearly 30 percent for the year. Cramer spoke with Spark's co-founder and CEO Jeff Marrazzo, who confirmed positive top-line results for a product used to treat the retinal dystrophies, a genetic condition that causes reduced or deteriorating vision.
"Last year we completed successfully a phase three clinical trial. It was .. a pivotal trial that was randomized and controlled for gene therapy in a genetic disease," Marrazzo said. "That is a significant milestone, and we now are busy preparing and are near substantial completion of the first marketing authorization submission that we have put to the FDA."
In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:
Brightcove: "Brightcove I think is a little risky. It's making a lot of money there and the stock has had a very big run. My take is don't buy, don't buy."
Sarepta Therapautics: "This is one of the highest risk stocks in the world. It's a binary stock; they either get approval or they don't. If they get approval, the stock has still doubled from $28. And if they don't get approval the stock can get crushed. I think it's way too risky for me."